CD274 and nasopharyngeal carcinoma: The analysis focused on the current landscape of clinical trials on the use of anti-PD-1/PD-L1 therapies in NPC, including characteristics of trials and the study design, the distribution of drugs, as well as the disease conditions being targeted.